Category Archives: Healthcare

Thursday’s Midday Stock Update: Second Sight Medical Products (EYES), Fuelcell Energy (FCEL), Heron Therapeutics (HRTX), 3D Systems (DDD), Pan American Silver (PAAS)

So far Thursday, May 13, NASDAQ is down -0.47% and the S&P is up 1.09%. Here are this morning’s most active stocks: Second Sight Medical Products (EYES – Research Report), Fuelcell Energy (FCEL – Research Report), Heron Therapeutics (HRTX –

A Director at Horizon Therapeutics (NASDAQ: HZNP) is Selling Shares

Yesterday, a Director at Horizon Therapeutics (HZNP – Research Report), Daniel William, sold shares of HZNP for $1.73M. See today’s analyst top recommended stocks >> The company has a one-year high of $97.20 and a one-year low of $43.81. Currently,

A Director at BioCryst (NASDAQ: BCRX) is Selling Shares

Yesterday, a Director at BioCryst (BCRX – Research Report), George Abercrombie, sold shares of BCRX for $88.9K. This is Abercrombie’s first Sell trade following 3 Buy transactions. Following George Abercrombie’s last BCRX Sell transaction on March 31, 2014, the stock

Xenon (XENE) Gets a Buy Rating from Leerink Partners

Leerink Partners analyst Marc Goodman reiterated a Buy rating on Xenon (XENE – Research Report) on May 11 and set a price target of $28.00. The company’s shares closed last Wednesday at $17.43. According to TipRanks.com, Goodman is a 3-star

Leerink Partners Keeps Their Buy Rating on Adamas Pharmaceuticals (ADMS)

Leerink Partners analyst Marc Goodman maintained a Buy rating on Adamas Pharmaceuticals (ADMS – Research Report) on May 10 and set a price target of $6.00. The company’s shares closed last Wednesday at $5.34. According to TipRanks.com, Goodman is a

Castle Biosciences (CSTL) Initiated with a Buy at Robert W. Baird

Castle Biosciences (CSTL – Research Report) received a Buy rating and a $73.00 price target from Robert W. Baird analyst Catherine Ramsey Schulte on May 11. The company’s shares closed last Wednesday at $52.11. According to TipRanks.com, Schulte is a